eversyn is a deeptech biotech startup redefining access to complex glycans and human milk oligosaccharides through a novel enzymatic cell-free synthesis platform. Originating from the Max Planck Institute, the team targets a billion-euro market in biopharma and nutrition. Their scalable, cost-effective technology enables groundbreaking advancements in antibody engineering and functional food ingredients. With first products launched and seed funding secured, eversyn is poised to become a key enabler in the glycoengineering revolution.

Key Milestones

• Selected for the German Accelerator – Asia Market Discovery Program
• Launched online sales of innovative nucleotide sugars and enzymes
• Secured €1.6 million in seed funding to scale production and advance technology applications in nutrition and biopharma